- Home
- TRNR vs RDHL Comparison
TRNR vs RDHL Comparison
Compare TRNR & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRNR | RDHL |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.3M |
| IPO Year | 2023 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TRNR | RDHL |
|---|---|---|
| Price | $2.30 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.9K | ★ 306.4K |
| Earning Date | 05-18-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,530,000.00 | N/A |
| Revenue This Year | $264.92 | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 114.31 | N/A |
| 52 Week Low | $0.19 | $0.48 |
| 52 Week High | $12.12 | $2.60 |
Technical Indicators
Market Signals| Indicator | TRNR | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 43.78 | 33.94 |
| Support Level | $1.10 | N/A |
| Resistance Level | $2.50 | $1.07 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 4.09 | 6.49 |
Price Performance
Historical ComparisonAbout TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.